Marché de la neuropathie périphérique induite par la chimiothérapie – Analyse des tendances et de la croissance | Année de prévision 2031

  • Report Code : TIPRE00028941
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 151
Buy Now

[Rapport de recherche]Le marché de la neuropathie périphérique induite par la chimiothérapie devrait atteindre 1 174,26 millions de dollars US d'ici 2028, contre 813,48 millions de dollars US en 2021 ; il devrait enregistrer un TCAC de 5,4 % de 2021 à 2028.



La neuropathie périphérique induite par la chimiothérapie est l'un des effets secondaires les plus fréquents causés par les agents antinéoplasiques. Cliniquement, il s'agit d'une neuropathie principalement sensorielle qui peut s'accompagner de modifications motrices et autonomes d'intensité et de durée variables. En raison de sa forte prévalence chez les patients cancéreux, la neuropathie périphérique induite par la chimiothérapie constitue un problème majeur pour les patients et les survivants du cancer ainsi que pour leurs prestataires de soins, notamment parce qu'il n'existe pas à l'heure actuelle de méthode unique efficace pour la prévenir ; de plus, les possibilités de traitement de ce syndrome sont limitées.



Aperçus stratégiques



Le rapport offre des aperçus et une analyse approfondie de la Marché de la neuropathie périphérique induite par la chimiothérapie (NPCI) mettant l'accent sur les tendances du marché, les progrès technologiques et la dynamique du marché. Il fournit également l'analyse du paysage concurrentiel des principaux acteurs du marché à travers le monde. En outre, le rapport inclut l'impact de la pandémie de COVID-19 sur le marché de la neuropathie périphérique induite par la chimiothérapie dans toutes les régions. La pandémie a créé à la fois une crise de santé publique et une crise économique dans le monde entier. Le marché mondial de la neuropathie périphérique induite par la chimiothérapie avant la pandémie était en croissance constante en raison de la régularité du dépistage du cancer, des consultations et des traitements. La première vague de COVID-19 a perturbé les consultations, les suivis et les dépistages des cas oncologiques. De plus, les perturbations des essais cliniques et de l'approvisionnement en médicaments des patients au début de la pandémie de COVID-19 ont eu un impact sur les domaines les plus cruciaux du marché de la neuropathie périphérique induite par la chimiothérapie. Un changement d'orientation vers le traitement rapide du COVID-19 a conduit à une négligence envers diverses autres conditions médicales. De plus, la diminution de la détection des cas de cancer et des séances de chimiothérapie pour le traitement a entravé la demande de diagnostics et de traitements de la neuropathie périphérique induite par la chimiothérapie.



Régions lucratives pour le marché de la neuropathie périphérique induite par la chimiothérapie



Aperçu du marché



Augmentation de la prévalence du cancer Stimule la croissance du marché de la neuropathie périphérique induite par la chimiothérapie

Le cancer est l'une des principales causes de décès dans le monde. Selon l'Organisation mondiale de la santé (OMS), le cancer a été signalé comme la première cause de décès chez les personnes de moins de 70 ans dans 183 pays et la quatrième cause de décès parmi la population de tous âges dans 123 pays du monde en 2019. De plus, selon les données publiées par l'OMS en mars 2021, différents types de cancer ont causé environ 10 millions de décès en 2020.



Formes de cancer les plus répandues dans le monde, 2020

La prévalence croissante du cancer a créé un fardeau pour les systèmes de santé à travers le monde, tout en renforçant la demande de chimiothérapie. La neuropathie périphérique induite par la chimiothérapie est un effet indésirable courant des médicaments anticancéreux neurotoxiques, tels que les médicaments dérivés du platine (cisplatine et oxaliplatine), les poisons du fuseau [taxanes (paclitaxel et docétaxel), alcaloïdes de la pervenche, vincristine, épothilones et éribuline], le bortézomib, et la thalidomide. La forte prévalence de la neuropathie périphérique induite par la chimiothérapie soulève des inquiétudes pour les patients atteints de cancer et les survivants, ainsi que pour leurs prestataires de soins de santé, en particulier parce qu'il n'existe pas de moyen efficace unique de prévenir cette maladie.



Dans un étude menée par «The Journal of the International Association for the Study of Pain” la prévalence de la neuropathie périphérique induite par la chimiothérapie a été rapportée à 68,1 % (57,7-78,4 lorsqu'elle est mesurée au cours du premier mois après la chimiothérapie, 60,0 % (36,4-81,6) au cours du troisième mois et 30,0 % (6,4-53,5) au cours du sixième mois ou plus tard Ainsi, l'incidence croissante de la neuropathie périphérique induite par la chimiothérapie avec la prévalence croissante du cancer stimule la croissance du marché de la neuropathie périphérique induite par la chimiothérapie.



Drug Class-Based Insights

Sur la base de la classe de médicaments, le marché de la neuropathie périphérique induite par la chimiothérapie est segmenté en stéroïdes, antidépresseurs, anti-épileptiques et narcotiques. En 2021, le segment des stéroïdes détenait la plus grande part du marché. Le segment anti-épileptiques devrait enregistrer le TCAC le plus rapide de 6,2 % au cours de la période de prévision.



Marché de la neuropathie périphérique induite par la chimiothérapie, par produit – 2020 et 2028

< TIP>

Informations basées sur le canal de distribution



Sur la base du canal de distribution, le marché de la neuropathie périphérique induite par la chimiothérapie est segmenté en pharmacie hospitalière, pharmacie de détail et pharmacie en ligne. En 2021, le segment de la pharmacie hospitalière détenait la plus grande part du marché. En outre, le segment des pharmacies de détail devrait afficher le TCAC le plus élevé de 5,9 % au cours de la période 2021-2028.



Les acteurs du marché de la neuropathie périphérique induite par la chimiothérapie (NPCI) se concentrent sur l'adoption de stratégies organiques telles que que le lancement et l'expansion de produits pour étendre leur empreinte et leur portefeuille de produits dans le monde entier, ainsi que pour répondre aux demandes croissantes.



Par géographie



Sur la base de la géographie, le marché de la neuropathie périphérique induite par la chimiothérapie est segmenté en Amérique du Nord (États-Unis, Canada et Mexique), Europe (Royaume-Uni, Allemagne, France, Italie, Espagne et reste de l'Europe), Asie-Pacifique (Chine, Japon, Inde, Australie, Corée du Sud et reste de l'Asie-Pacifique), Moyen-Orient et Afrique (EAU, Arabie saoudite, Afrique du Sud et reste du Moyen-Orient et Afrique) et Amérique du Sud et centrale (Brésil, Argentine et reste du Amérique du Sud et centrale).



Profils des entreprises




  1. Regenacy Pharmaceuticals, Inc.
  2. < CONSEIL>
  3. Asahi Kasei Pharma Corporation

  4. Novaremed

  5. Makscientific, Llc

  6. Wex Pharmaceuticals Inc.

  7. Sova Pharmaceuticals, Inc.

  8. Kineta, Inc.

  9. Aptinyx Inc.

  10. Apexian Pharmaceuticals, Inc.

  11. Winsantor, Inc.



Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What is the chemotherapy induced peripheral neuropathy market?

Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most frequent side effects caused by antineoplastic agents. Clinically, CIPN is a mostly sensory neuropathy that may be accompanied by motor and autonomic changes of varying intensity and duration. Due to its high prevalence among cancer patients, CIPN constitutes a major problem for both cancer patients and survivors as well as for their health care providers, especially because, at the moment, there is no single effective method of preventing CIPN; moreover, the possibilities of treating this syndrome are very limited.

What are the driving factors for the chemotherapy induced peripheral neuropathy market across the country?

The factors that are driving and restraining factors that will affect the chemotherapy induced peripheral neuropathy market in the coming years. Major factors driving the market growth include the increasing prevalence of cancer and increasing preference for chemotherapy. Additionally, the growing clinical trials for chemotherapeutic drugs is likely to emerge as a significant future trend in the market during the forecast period. However, lack of consolidated guidelines for chemotherapy hamper the chemotherapy induced peripheral neuropathy market growth.

Which segment is dominating the chemotherapy induced peripheral neuropathy market?

The chemotherapy induced peripheral neuropathy market, by drug class, is bifurcated into steroids, antidepressants, anti-seizure medicines, and narcotics. In 2021, the steroids segment held the largest share of the market. The anti-seizure medicines segment of the chemotherapy induced peripheral neuropathy market is expected to witness growth in its demand at the fastest CAGR during the forecast period.

Who are the major players in market the chemotherapy induced peripheral neuropathy market?

The chemotherapy induced peripheral neuropathy market majorly consists of the players such as Regenacy Pharmaceuticals, Inc, Asahi Kasei Pharma Corporation., Novaremed, Makscientific, Llc, Wex Pharmaceuticals Inc., Sova Pharmaceuticals, Inc., Kineta, Inc., Aptinyx Inc., Apexian Pharmaceuticals, Inc., and Winsantor, Inc. amongst others.

The List of Companies - Chemotherapy Induced Peripheral Neuropathy Market

  1. REGENACY PHARMACEUTICALS, INC
  2. ASAHI KASEI PHARMA CORPORATION
  3. NOVAREMED
  4. MAKSCIENTIFIC, LLC
  5. WEX PHARMACEUTICALS INC
  6. SOVA PHARMACEUTICALS, INC
  7. KINETA, INC.
  8. APTINYX INC.
  9. APEXIAN PHARMACEUTICALS, INC.
  10. WINSANTOR, INC

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports